Shunt placement through the sclera
US-2015290035-A1 · Oct 15, 2015 · US
US9592154B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9592154-B2 |
| Application number | US-201514834158-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 24, 2015 |
| Priority date | Dec 8, 2011 |
| Publication date | Mar 14, 2017 |
| Grant date | Mar 14, 2017 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
An intraocular shunt can be manufactured using a system that includes a liquid bath and a wire, which is moved through the bath. When moved through the bath, the wire is coated with a material, such as gelatin. For example, the liquid bath can have a top layer, including water, and a bottom layer, including gelatin. The coated wire passes through an aperture formed in a plate component of the system. The gelatin can be dried on the wire in a humidity-controlled space, thereby forming the shunt.
Opening claim text (preview).
What is claimed is: 1. A method for manufacturing a gelatin shunt, the method comprising: moving a wire through a liquid bath, comprising a top layer and a bottom gelatin layer having a drug, to coat the wire with gelatin; moving the gelatin-coated wire through an aperture; and drying the gelatin on the wire in a humidity-controlled space, thereby manufacturing a drug-impregnated gelatin shunt. 2. The method of claim 1 , wherein the drug comprises an anti-mitotic pharmaceutical. 3. The method of claim 2 , wherein the drug comprises Mitomycin-C. 4. The method of claim 1 , wherein the drug comprises a steroid or antifibrotic agent. 5. The method of claim 1 , wherein the drug comprises 5-Fluorouracil or an anti-VEGF. 6. The method of claim 1 , wherein the drug comprises an antimicrobial agent. 7. The method of claim 6 , wherein the drug further comprises a non-pathogenic bacterium. 8. The method of claim 1 , wherein the drug comprises an antiseptic. 9. The method of claim 1 , wherein the drug comprises a time-release pharmaceutical or biological agent. 10. The method of claim 1 , wherein the top layer comprises water. 11. The method of claim 10 , wherein the moving the wire comprises moving the wire through the top layer to encapsulate the gelatin-coated wire with water. 12. The method of claim 1 , wherein after the drying, the shunt comprises a uniform shape and a uniform cross-section. 13. The method of claim 1 , further comprising controlling humidity of the space by drying the gelatin on the wire in the presence of an ultrasonic water fog. 14. The method of claim 1 , wherein the aperture is positioned above the bottom layer. 15. A method for manufacturing a gelatin shunt, the method comprising: moving a wire through a liquid bath to coat the wire with gelatin; drawing the gelatin-coated wire through an aperture, thereby controlling a cross-sectional thickness of the gelatin coating on the wire; drying the gelatin on the wire in a humidity-controlled space, in the presence of an ultrasonic water fog, thereby manufacturing a gelatin shunt; and coating the shunt with a drug. 16. The method of claim 15 , wherein the drug comprises an anti-mitotic pharmaceutical. 17. The method of claim 16 , wherein the drug comprises Mitomycin-C. 18. The method of claim 15 , wherein the drug comprises a steroid or antifibrotic agent. 19. The method of claim 15 , wherein the drug comprises 5-Fluorouracil or an anti-VEGF. 20. The method of claim 15 , wherein the drug comprises an antimicrobial agent. 21. The method of claim 20 , wherein the drug further comprises a non-pathogenic bacterium. 22. The method of claim 15 , wherein the drug comprises an antiseptic. 23. The method of claim 15 , wherein the drug comprises a time-release pharmaceutical or biological agent. 24. The method of claim 15 , wherein the coating comprises coating an exterior surface of the shunt. 25. The method of claim 15 , wherein the coating comprises coating an interior surface of the shunt. 26. The method of claim 15 , wherein the liquid bath comprises a top layer and a bottom layer, the top layer comprising water, and the bottom layer comprising gelatin. 27. The method of claim 15 , wherein the gelatin-coated wire extends vertically during the drying step.
Apparatus for modifying intraocular pressure, e.g. for glaucoma treatment (drainage implants in general A61M27/002) · CPC title
for treating work of indefinite length · CPC title
Hot-dipping or immersion processes for applying the coating material in the molten state without affecting the shape; Apparatus therefor · CPC title
Designing or manufacturing processes · CPC title
implantable in, or in contact with, the eye, e.g. ocular inserts · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.